News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

IECURE Granted Expansion Approval by U.K. MHRA for OTC-HOPE Study with ECUR-506

Thursday, March 07, 2024

IECURE Inc a pioneering gene editing company focused on addressing liver disorders with significant unmet medical needs has announced that it has received approval from the UK Medicines

Fibrocor Therapeutics and McQuade Center for Strategic Research and Development Partner to Advance Alport Syndrome Program

Wednesday, March 06, 2024

Fibrocor Therapeutics Inc a leader in developing innovative treatments for fibrosis has established a research and development collaboration with the McQuade Center for Strategic Research

Bit.bio and the Michael J. Fox Foundation (MJFF) Initiate Partnership for Human Cell Products in Parkinson's Disease Research and Drug Discovery

Wednesday, March 06, 2024

Bitbio and The Michael J Fox Foundation for Parkinsons Research MJFF have initiated a groundbreaking partnership aimed at transforming the treatment of Parkinsons disease PD

Grace Science, LLC Starts Clinical Trial for GS-100, an AAV9 Gene Therapy Targeting NGLY1 Deficiency, Treating First Patient

Wednesday, March 06, 2024

Grace Science LLC announced today that they have initiated an openlabel Phase clinical trial for GS an AAV gene replacement therapy aimed at treating NGLY Deficiency

EU Approves Two Applications for Datopotamab Deruxtecan in Advanced Nonsquamous Non-Small Cell Lung Cancer and HR Positive, HER2 Negative Breast Cancer Patients

Tuesday, March 05, 2024

The European Medicines Agency has given its validation to two marketing authorization applications submitted by Daiichi Sankyo and AstraZeneca for their innovative drug datopotamab deruxtecan

A2 Bio Secures FDA Orphan Drug Designation for New Cell Therapy Program A2B530 Targeting Colorectal Cancer

Monday, March 04, 2024

A Biotherapeutics Inc has recently revealed that their cell therapy product AB has secured Orphan Drug Designation from the US Food and Drug Administration for treating a specific subset of colorectal

Precisio Biotix Therapeutics Completes Acquisition of London-Based CC Bio, Strengthening Antibacterial Platform and Talent Roster

Saturday, March 02, 2024

Precisio Biotix Therapeutics has recently announced the acquisition of CC Bio the creator of the ZEUS antibacterial lysin platform This acquisition is seen as a strategic move complementing Precisios

GENESIS Pharma Secures Exclusive Distribution Agreement with Regeneron Pharmaceuticals to Commercialize Cemiplimab in Greece, Cyprus, and Malta

Saturday, March 02, 2024

GENESIS Pharma a regional biopharmaceutical company specializing in bringing innovative medicines for severe and rare diseases to Central and Eastern Europe has announced an exclusive distribution

Ariceum Therapeutics Granted Regulatory Approval in the UK for Phase I Clinical Trial of First-of-its-Kind Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma

Friday, March 01, 2024

Ariceum Therapeutics a private biotech company specializing in the development of radiopharmaceutical products for the diagnosis and treatment of challenging cancers is pleased to

Alamar Biosciences and ALZpath, Inc. Announce Strategic Collaboration for pTau217 Antibody to Further Alzheimer's Disease Research

Friday, March 01, 2024

Alamar Biosciences a company specializing in precision proteomics for early disease detection is excited to announce a strategic collaboration with ALZpath a prominent developer of diagnostic